United Therapeutics Dirección
Dirección controles de criterios 3/4
United Therapeutics' El consejero delegado es Martine Rothblatt , nombrado en Jan 1996, tiene un mandato de 28.08 años. la remuneración anual total es $5.32M , compuesta por 26.3% salario y 73.7% primas, incluidas acciones y opciones de la empresa. posee directamente 1.37% de las acciones de la empresa, por valor de $138.42M . La antigüedad media del equipo directivo y del consejo de administración es de 14.8 años y 21.3 años respectivamente.
Información clave
Martine Rothblatt
Chief Executive Officer (CEO)
US$5.3m
Compensación total
| Porcentaje del salario del CEO | 26.3% |
| Permanencia del CEO | 28.3yrs |
| Participación del CEO | 1.4% |
| Permanencia media de la dirección | 15yrs |
| Promedio de permanencia en la Junta Directiva | 21.5yrs |
Actualizaciones recientes de la dirección
Recent updates
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05
United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Why Hold United Therapeutics After Shares Doubled?
Jun 08With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting
May 06Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Compensación vs. Mercado: Martine($USD5.32M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD12.14M).
Compensación vs. Ingresos: Martineha aumentado más de un 20% en el último año.
CEO
Martine Rothblatt (68 yo)
28.3yrs
Permanencia
US$5,322,204
Compensación
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 28.3yrs | US$5.32m | 1.37% $ 153.3m | |
| President & COO | 7.8yrs | US$2.83m | 0.0052% $ 586.4k | |
| CFO & Treasurer | 11.3yrs | US$2.01m | 0.0031% $ 349.1k | |
| Executive VP | 28.3yrs | US$2.31m | 0.078% $ 8.7m | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Associate Vice President of Human Resources | no data | sin datos | sin datos | |
| Senior Vice President of Strategic Operations & Logistics | no data | sin datos | sin datos | |
| Executive VP of Technical Operations | 15yrs | sin datos | sin datos | |
| Senior Vice President of Product Development | no data | sin datos | sin datos | |
| Senior VP & Chief Medical Officer | no data | sin datos | sin datos |
15.0yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: UTHREl equipo directivo de la empresa es veterano y experimentado (14.7 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 28.3yrs | US$5.32m | 1.37% $ 153.3m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 22.3yrs | US$485.37k | 0.024% $ 2.7m | |
| Independent Director & Member of the Scientific Advisory Board | 21.6yrs | US$515.37k | 0.028% $ 3.1m | |
| Independent Director & Member of the Scientific Advisory Board | 22.3yrs | US$495.35k | 0.0037% $ 416.3k | |
| Independent Vice Chairman & Lead Independent Director | 21.5yrs | US$562.98k | 0.0024% $ 263.0k | |
| Independent Director | 20.8yrs | US$520.35k | 0.0089% $ 994.8k | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 14.3yrs | US$500.37k | 0.048% $ 5.3m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 15yrs | US$520.35k | 0.033% $ 3.7m | |
| Independent Director | 9.4yrs | US$485.37k | 0.0077% $ 866.1k |
21.5yrs
Permanencia media
75yo
Promedio de edad
Junta con experiencia: UTHRLos consejos de administración de la empresa son veteranos y experimentados ( 21.2 años de permanencia media en el cargo).